Russia to launch production of Fabry disease drug this year

A full cycle of production of a drug for the treatment of Fabry disease will be launched in Russia this year, reports The Pharma Letter’s local correspondent.

The project will be implemented by the Russian drugmaker Petrovax together with the Gamaleya Research Institute of Epidemiology and Microbiology, one of Russia’s leading medical and research institutions.

The new drug is known as Fabagal, and the beginning of its commercial production will allow the Russian state budget to at least partially refuse from procurements of the original drug Fabrazyme based on the same active ingredient of agalsidase beta from Genzyme, the US subsidiary of French pharma major Sanofi (Euronext: SAN).